Daraxonrasib highlights overall survival benefit in patients with metastatic pancreatic cancer

Revolution Medicines recently delivered a result that experts are calling unprecedented in one of oncology’s most feared diseases. Its oral drug daraxonrasib has nearly doubled survival time in patients with previously treated metastatic pancreatic cancer — a condition where meaningful progress has eluded the field for decades.

Note that in a global Phase 3 trial, patients taking daraxonrasib once daily survived a median of 13.2 months compared to just 6.7 months for those receiving standard intravenous chemotherapy, which is a difference of more than six months. The drug also cut the risk of death by 60%.

Brian Wolpin, professor of medicine at Harvard Medical School and director of the Hale Family Center for Pancreatic Cancer Research at Dana-Farber Cancer Institute, who led the trial, said the results represent “a clear and highly meaningful step forward” for patients whose cancer has progressed on prior treatment. He added: “I believe that this new approach is a very important advance for the field that I expect will be practice-changing for physicians.”

Why This Matters

Pancreatic cancer is driven by mutations in a family of proteins called RAS in more than 90% of cases. These mutations have historically been considered “undruggable”  a wall that researchers spent over 15 years trying to break through. Daraxonrasib is the first drug of its kind to directly block these RAS proteins while they are in their active, cancer-driving state, and crucially, it works across the wide variety of RAS mutations seen in pancreatic tumours rather than targeting just one specific variant.

The drug was well tolerated with no new safety concerns identified a meaningful finding given that the chemotherapy it outperformed carries significant side effect burdens for already vulnerable patients.

What the CEO Said

Mark Goldsmith, Revolution Medicines’ chief executive, called the results “a potentially transformative advance for patients” that he believes will “redefine the treatment landscape.” He was equally direct about the commercial and scientific significance of the moment, stating the results “firmly validate our pioneering approach to targeting common RAS-addicted cancers” — an approach built on more than 15 years of investment in what he described as “groundbreaking scientific research.”

Goldsmith added that the company is “moving with urgency toward global regulatory submissions,” signalling an aggressive timeline to bring the drug to market.

What Happens Next

Revolution Medicines plans to submit the data to regulators worldwide, including the FDA under an expedited review programme, and will present the full results at the 2026 American Society of Clinical Oncology Annual Meeting — one of the year’s most closely watched cancer conferences. The company already has daraxonrasib running in three further Phase 3 trials in pancreatic cancer, including as a first-line treatment, as well as a separate trial in lung cancer.

If approved, this would be the first targeted oral therapy for pancreatic cancer and potentially the most significant advance the field has seen in a generation.

---

---

Related Topics and Keywords

BiopharmInvesting, ClinicalTrials, Daraxonrasib, FDA, MedicalBreakthrough, metastatic pancreatic cancer, Oncology, RASInhibitor, RevolutionMedicines